再発卵巣がんに対するペムブロリズマブとベバシズマブ併用化学療法、それに続くペムブロリズマブ、ベバシズマブ、オラパリブ併用療法

基本情報

NCT ID: NCT05158062
ステータス: 不明
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 35
治験依頼者名: Saitama Medical University International Medical Center

概要

This trial is a multicenter, single-arm, phase II study evaluating the efficacy of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35 patients from multiple study sites in Japan.

対象疾患

Carcinoma, Ovarian Epithelial

介入

pembrolizumab(BIOLOGICAL)

olaparib(DRUG)

bevacizumab(BIOLOGICAL)

carboplatin(DRUG)

paclitaxel(DRUG)

docetaxel(DRUG)

依頼者（Sponsor）

Kosei Hasegawa, Md, Phd(OTHER)

実施施設 (1)

Saitama Medical Uiversity International Medical Center

Hidaka, Saitama, Japan(RECRUITING)